<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04247984</url>
  </required_header>
  <id_info>
    <org_study_id>NCC-000583</org_study_id>
    <nct_id>NCT04247984</nct_id>
  </id_info>
  <brief_title>A Comparison of mXELIRI Regimen and FOLFIRI Combined Bevacizumab Regimen as First-line Chemotherapy Regimen for Metastatic Colorectal Cancer</brief_title>
  <official_title>An Efficacy and Safety Study of mXELIRI Versus. FOLFIRI + Bevacizumab Therapy as First-line Chemotherapy in Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Henan Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Liaoning Tumor Hospital &amp; Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangsu Cancer Institute &amp; Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical&#xD;
      trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin®)&#xD;
      plus mXELIRI compared with bevacizumab (Avastin®) plus FOLFIRI as first-line treatment in&#xD;
      patients with metastatic colorectal cancer (mCRC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II, multicenter，randomized, two arms, open-labeled, controlled clinical&#xD;
      trial. This trial was conducted to evaluate the efficacy and safety of bevacizumab (Avastin®)&#xD;
      plus mXELIRI compared with bevacizumab (Avastin®) plus FOLFIRI in not previously treated&#xD;
      patients with metastatic colorectal cancer (mCRC). In experimental group, untreated patients&#xD;
      with metastatic colorectal cancer will receive Irinotecan 150 mg/m2 (D1, q2w) , Xeloda&#xD;
      2000mg/m2 (D1-10, q2w) and bevacizumab 5mg/kg (D1, q2w) for 6-9 cycles as the first-line&#xD;
      treatment. While in control group, patients with metastatic colorectal cancer will receive&#xD;
      Irinotecan 180 mg/m2 (D1, q2w) , CF 300mg/m2 (D1 q2w), 5FU 400mg/m2, D1 2400 mg/m2, civgtt&#xD;
      44h (q2w) and bevacizumab 5mg/kg (D1, q2w) for 6-9 cycles as the first-line treatment.The&#xD;
      primary endpoint is progression-free survival. Overall survival, Objective Response rate,&#xD;
      adverse event and life quality will be assessed as secondary outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2018</start_date>
  <completion_date type="Anticipated">October 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>6 Months</time_frame>
    <description>Time from the date of enrollment to the earlier of the date of confirmed progression or death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>6 Months</time_frame>
    <description>Proportion of eligible patients with measurable lesions with a best overall response of CR or PR assessed by the attending physician.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 Year</time_frame>
    <description>Time from the date of enrollment to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events</measure>
    <time_frame>6 Months</time_frame>
    <description>The incidence of adverse events as graded by NCI-CTCAE v 4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL) Questionnaire</measure>
    <time_frame>6 Months</time_frame>
    <description>Determined by European Organization for Research and Treatment of Cancer (EORTC) Quality-of-Life Questionnaire-Core 30 (QLQ-C30) Score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>mXELIRI+ Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>5 mg/kg intravenously administered on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_label>mXELIRI+ Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>2000mg/m2/day oral on day 1 to day 10 of a 2-week cycle.</description>
    <arm_group_label>mXELIRI+ Bevacizumab</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>180 mg/m2 intravenously administered on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI + Bevacizumab</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-FU</intervention_name>
    <description>400 mg/m2 intravenous bolus on day 1 and 2400 mg/m2 continuous infusion over 44 hours of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI + Bevacizumab</arm_group_label>
    <other_name>Fluorouracil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CF</intervention_name>
    <description>300 mg/m2 intravenously administered on day 1 of a 2-week cycle.</description>
    <arm_group_label>FOLFIRI + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>150 mg/m2 intravenously administered on day 1 of a 2-week cycle.</description>
    <arm_group_label>mXELIRI+ Bevacizumab</arm_group_label>
    <other_name>CPT-11</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent;&#xD;
&#xD;
          2. ECOG≤1;&#xD;
&#xD;
          3. Age≥18；&#xD;
&#xD;
          4. Histologically or cytologically confirmed unresectable metastatic colorectal cancer&#xD;
             with no previous chemotherapy or molecular targeted therapy;&#xD;
&#xD;
          5. At least one evaluable lesion per RECIST (Response Evaluation Criteria in Solid&#xD;
             Tumors) 1.1;&#xD;
&#xD;
          6. life expectancy &gt;12 weeks;&#xD;
&#xD;
          7. Adequate bone marrow and organ function. Hb≥9 G/L; Absolute neutrophil ≥ 1.5 G/L; PLT&#xD;
             ≥100 G/L ;ALT/AST ≤2 ULN or ≤5ULN with liver metastases;ALP ≤2.5 ULN or ≤5ULN with&#xD;
             liver metastases or ≤10ULN with bone metastases ; TBIL ≤1.5 ULN; Cr≤1.0 ULN;&#xD;
&#xD;
          8. Urinary protein excretion &lt; 2+ (dipstick). If &gt; or equal 2+ proteinuria is detected&#xD;
             with dipstick, a 24-hour period urine test will be performed and the result should be&#xD;
             &lt; or equal to 1 g/24 hours to permit the inclusion of the patient in the clinical&#xD;
             trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women；&#xD;
&#xD;
          2. Sexually active women (of childbearing potential) or men unwilling to adopt an&#xD;
             effective method of birth control during the course of the study；&#xD;
&#xD;
          3. Previous treatment with Irinotecan or anti-VEGF antibodies;&#xD;
&#xD;
          4. Any previous malignancy within 5 years prior to study entry, except for cured basal&#xD;
             cell carcinoma of skin or carcinoma-in-situ of the uterine cervix;&#xD;
&#xD;
          5. History of acute coronary syndromes (including myocardial infarction and unstable&#xD;
             angina) within 6 months prior to study entry, or history or evidence of current ≥&#xD;
             Class II congestive heart failure as defined by New York Heart Association (NYHA);&#xD;
&#xD;
          6. Uncontrolled hypertension and severe arrhythmia requiring drug treatment;&#xD;
&#xD;
          7. Present with non-healing fractures or wounds of skin;&#xD;
&#xD;
          8. History of previous abdominal fistula, gastrointestinal perforation or intra-abdominal&#xD;
             abscesses within 6 months before randomization;&#xD;
&#xD;
          9. Major surgery, open surgical biopsy or significant traumatic injury within 4 weeks or&#xD;
             needle biopsy within 7 days before randomization before randomization；&#xD;
&#xD;
         10. Evidence or history of bleeding diathesis or coagulopathy；&#xD;
&#xD;
         11. Known or suspected allergy or hypersensitivity to any component of Bevacizumab,&#xD;
             xeloda, irinotecan, or 5-FU/LV;&#xD;
&#xD;
         12. Clinical or radiological evidence of CNS metastases;&#xD;
&#xD;
         13. History of unexpected serious adverse events to fluoropyrimidine treatments or known&#xD;
             dihidropyrimidine dehydrogenase (DPD) deficiency;&#xD;
&#xD;
         14. Patients subjected to organ allografts who require immunosuppressive treatment;&#xD;
&#xD;
         15. Prior adjuvant or neoadjuvant treatment for metastatic colorectal cancer is allowed,&#xD;
             as long as it has concluded at least 6 months before beginning the treatment of the&#xD;
             study;&#xD;
&#xD;
         16. If adjuvant treatment has previously been administered, the patients cannot have shown&#xD;
             progression of the disease during treatment nor during the 6 months following&#xD;
             termination thereof;&#xD;
&#xD;
         17. Prior radiotherapy is allowed if it has not been administered in the target lesions&#xD;
             selected for this study, unless progression of said lesions in the irradiated field is&#xD;
             documented, and as long as treatment has concluded at least 4 weeks before beginning&#xD;
             the study;&#xD;
&#xD;
         18. Prior surgical treatment of the disease in stage IV is allowed;&#xD;
&#xD;
         19. Use of full dose of oral or parenteral anticoagulants ( at least 10 days before the&#xD;
             initial study treatment or thrombolytic agents. Low dose of warfarin is allowed, with&#xD;
             an INR ≤ 1.5;&#xD;
&#xD;
         20. Subject requiring chronic use of high dose aspirin (&gt; 325 m/day) or non-steroidal&#xD;
             anti-inflammatory treatment ;&#xD;
&#xD;
         21. Received any investigational drug or agent/ procedure, i.e. participation in another&#xD;
             treatment trial within 4 weeks of randomisation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cancer Hospital &amp; Institute, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aiping Zhou, M.D</last_name>
      <phone>8610-87788145</phone>
      <email>zhouap1825@126.com</email>
    </contact>
    <investigator>
      <last_name>Yongkun Sun, M.D</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Aiping Zhou</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <keyword>XELIRI</keyword>
  <keyword>FOLFIRI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

